Nephron Pharmaceuticals Corporation   Report issue

For profit Phase 2 Phase 3
Founded: Florida NY United States (1937)
Status: No NME R&D (1937)

Organization Overview

First Clinical Trial
2014
NCT02059278
First Marketed Drug
1981
isoetharine (bronkosol)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

NEPHRON | Nephron Pharmaceuticals Corporation

Active Ingredients

Marketed Drugs (8)

albuterol (proventil) (1997)

budesonide (rhinocort) (2009)

ipratropium (atrovent) (2001)

isoetharine (bronkosol) (1981)

ketorolac (acuvail) (2020)

metaproterenol (alupent) (1988)

sodium chloride (2020)

water (2021)

Drugs in Phase 3 Trials (1)

latanoprost (xalatan) (1 trial)

Drugs in Phase 2 Trials (1)

tiotropium (spiriva) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Hypertension (Phase 3)

Ocular Hypertension (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2